The state of Wisconsin currently has 10 active clinical trials seeking participants for Alzheimer's Disease research studies. These trials are conducted in various cities, including Milwaukee, Madison, Green Bay and Marshfield.
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
Recruiting
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's diseas... Read More
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
06/19/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)
Interventions for Patients With Alzheimer's Disease and Dysphagia
Recruiting
The overall purpose of this project is to develop effective dysphagia rehabilitative interventions for patients with Alzheimer's Disease and related dementias at risk for pneumonia development.
Gender:
All
Ages:
Between 50 years and 99 years
Trial Updated:
06/18/2024
Locations: University of Wisconsin-Madison, Madison, Wisconsin
Conditions: Dementia, Dysphagia, Alzheimer Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
Recruiting
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
06/13/2024
Locations: Local Institution - 0065, Madison, Wisconsin
Conditions: Alzheimer Disease, Early Onset
ScentAware and OCT in MCI vs HC
Recruiting
The goal of this clinical trial is to learn whether a new smell test works as well as the standard clinical smell test, if there is a link between sense of smell and variations in the retina, and if these results could be used as a way to identify early stages of Alzheimer's disease. The main questions it aims to answer are: Whether the test is as effective and reliable as the standard test Whether there is a link between the results of the smell test and the structure of the back of the eye P... Read More
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
05/29/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Alzheimer Disease, Early Onset
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
Recruiting
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
05/16/2024
Locations: Spaulding Clinical Research, West Bend, Wisconsin
Conditions: Alzheimer's Disease
The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's
Recruiting
The LUCINDA Trial is a three-site, phase II, randomized, double-blind, placebo-controlled study of leuprolide acetate (Eligard) in women with Mild Cognitive Impairment or Alzheimer's Disease taking a stable dose of a cholinesterase inhibitor medication like donepezil. Its objective is to assess the efficacy of a 48-week regimen of leuprolide (22.5 mg per 12 weeks) compared to placebo on cognitive function, global function and plasma and neuroimaging biomarkers.
Gender:
Female
Ages:
Between 60 years and 120 years
Trial Updated:
04/22/2024
Locations: University of Wisconsin - Madison, Madison, Wisconsin
Conditions: Alzheimer Disease, Mild Cognitive Impairment
Dementia Care Partner Hospital Assessment Tool
Recruiting
The purpose of this study is to see whether an adapted questionnaire called the Care Partner Hospital Assessment Tool (CHAT) for care partners of hospitalized patients living with Alzheimer's disease and related dementias (ADRD) (CHAT-AD) can help people with dementia receive better care after they go home from the hospital. Participants will be a care partner ('family member or friend') who provides unpaid care to a hospitalized adult relative or partner to help them take care of themselves bec... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Alzheimer Disease, Dementia
Trial-Ready Cohort-Down Syndrome (TRC-DS)
Recruiting
The purpose of the Trial-Ready Cohort - Down Syndrome (TRC-DS) is to enroll 120 healthy adults with Down syndrome (DS), between the ages of 25-55, into a trial ready cohort (TRC), and up to 250 participants in total including co-enrolled in the Alzheimer Biomarkers Consortium - Down Syndrome (ABC-DS) study. Participants enrolled in the TRC-DS will undergo longitudinal cognitive and clinical assessment, genetic and biomarker testing, as well as imaging and biospecimen collection. Using these outc... Read More
Gender:
All
Ages:
Between 25 years and 55 years
Trial Updated:
03/06/2024
Locations: University of Wisconsin - Madison, Waisman Center, Co-Enrolling through ABC-DS Only, Madison, Wisconsin
Conditions: Down Syndrome, Alzheimer Disease, Dementia
Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders
Recruiting
The goal of this clinical trial is to compare the Hospital Elder Life Program (HELP) with a family-augmented version of HELP (FAM-HELP), that includes family members and care partners, for the prevention of delirium in older patients during hospital admission. The main objectives of the trial are the following: To compare the effectiveness of FAM-HELP and HELP in reducing both the incidence of delirium and its severity. To compare the effectiveness of FAM-HELP and HELP in improving patient- and... Read More
Gender:
All
Ages:
70 years and above
Trial Updated:
02/14/2024
Locations: Meriter Hospital, Madison, Wisconsin
Conditions: Delirium, Neurocognitive Disorders, Mild Cognitive Impairment, Alzheimer Disease, Aging, Family Support, Family Members, Caregiver Burden, Implementation Science, Patient Satisfaction
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
Recruiting
The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial). This study will also evaluate the long-term safety and tolerabili... Read More
Gender:
All
Ages:
Between 55 years and 80 years
Trial Updated:
02/06/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease